Mutual of America Capital Management LLC increased its holdings in shares of Catalent Inc (NYSE:CTLT) by 7.2% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 122,855 shares of the company’s stock after acquiring an additional 8,266 shares during the period. Mutual of America Capital Management LLC owned about 0.08% of Catalent worth $5,596,000 at the end of the most recent reporting period.
Several other institutional investors have also modified their holdings of the company. Nelson Van Denburg & Campbell Wealth Management Group LLC acquired a new position in Catalent in the second quarter valued at about $145,000. Moneta Group Investment Advisors LLC boosted its position in Catalent by 105.0% in the second quarter. Moneta Group Investment Advisors LLC now owns 3,515 shares of the company’s stock valued at $147,000 after buying an additional 1,800 shares in the last quarter. CIBC Asset Management Inc acquired a new position in Catalent in the third quarter valued at about $217,000. Chicago Equity Partners LLC acquired a new position in Catalent in the third quarter valued at about $237,000. Finally, Rehmann Capital Advisory Group boosted its position in Catalent by 1,895.9% in the second quarter. Rehmann Capital Advisory Group now owns 5,309 shares of the company’s stock valued at $222,000 after buying an additional 5,043 shares in the last quarter. Institutional investors and hedge funds own 96.77% of the company’s stock.
Shares of NYSE CTLT opened at $36.32 on Friday. Catalent Inc has a 1-year low of $34.24 and a 1-year high of $47.87. The stock has a market capitalization of $5.42 billion, a price-to-earnings ratio of 22.75, a P/E/G ratio of 2.33 and a beta of 1.44. The company has a quick ratio of 1.61, a current ratio of 2.05 and a debt-to-equity ratio of 1.44.
Catalent (NYSE:CTLT) last announced its earnings results on Tuesday, November 6th. The company reported $0.28 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.24 by $0.04. Catalent had a net margin of 2.65% and a return on equity of 19.13%. The company had revenue of $551.80 million during the quarter, compared to the consensus estimate of $582.44 million. During the same period in the previous year, the firm posted $0.21 earnings per share. The company’s revenue was up 1.5% on a year-over-year basis. On average, equities research analysts anticipate that Catalent Inc will post 1.63 earnings per share for the current year.
A number of equities analysts have commented on the stock. Zacks Investment Research upgraded shares of Catalent from a “sell” rating to a “hold” rating in a research report on Monday, October 1st. Morgan Stanley set a $46.00 price target on shares of Catalent and gave the company a “buy” rating in a research report on Monday, December 3rd. ValuEngine upgraded shares of Catalent from a “hold” rating to a “buy” rating in a research report on Monday, November 12th. Royal Bank of Canada set a $44.00 price target on shares of Catalent and gave the company a “buy” rating in a research report on Wednesday, November 7th. Finally, Robert W. Baird assumed coverage on shares of Catalent in a research report on Thursday, November 15th. They issued an “outperform” rating on the stock. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have given a buy rating to the stock. Catalent presently has a consensus rating of “Buy” and a consensus target price of $48.00.
In related news, Director John J. Greisch bought 13,000 shares of the company’s stock in a transaction on Thursday, November 8th. The stock was bought at an average cost of $37.61 per share, with a total value of $488,930.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider John R. Chiminski sold 130,545 shares of the business’s stock in a transaction that occurred on Monday, October 1st. The stock was sold at an average price of $45.32, for a total transaction of $5,916,299.40. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 184,335 shares of company stock valued at $8,161,727. Insiders own 1.40% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This piece of content was first reported by American Banking News and is owned by of American Banking News. If you are reading this piece of content on another publication, it was stolen and reposted in violation of US and international trademark and copyright legislation. The correct version of this piece of content can be viewed at https://www.americanbankingnews.com/2018/12/08/mutual-of-america-capital-management-llc-acquires-8266-shares-of-catalent-inc-ctlt.html.
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel Technologies, Biologics and Specialty Drug Delivery, Oral Drug Delivery, and Clinical Supply Services. The Softgel Technologies segment formulates, develops, and manufactures prescription and consumer soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations.
Featured Story: Put Option
Want to see what other hedge funds are holding CTLT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Catalent Inc (NYSE:CTLT).
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.